Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

2019 Genitourinary Cancers Symposium

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses current models used to estimate the risk of recurrence as well as genomic data that could help pinpoint individual tumor biology.

Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?

Jason A. Efstathiou, MD, DPhil, of Massachusetts General Hospital, discusses the debate over treating muscle-invasive bladder cancer with radical cystectom...

Bladder Cancer

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel

Thomas Powles, MD, PhD, of Queen Mary University of London, discusses phase III study findings on ramucirumab plus docetaxel vs placebo plus docetaxel in patients with advanc...

Prostate Cancer

Howard I. Scher, MD, on Prostate Cancer: Circulating Tumor Cells as a Surrogate Endpoint for Survival

Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials o...

Kidney Cancer

Immunotherapy

Brian I. Rini, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Results From the KEYNOTE-426 Trial on Pembrolizumab Plus Axitinib vs Sunitinib

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and Thomas Powles, MD, PhD, of Queen Mary University of London, discuss their study find...

Prostate Cancer

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Nicholas J. van As, MD, of The Royal Marsden NHS Foundation Trust, discusses an analysis of acute toxicity in the PACE-B study, which compared stereotactic body radiotherapy ...

Sep

Today In Oncology

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

Related Videos

Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Results From the RANGE Trial on Ramucirumab and Docetaxel

Howard I. Scher, MD, on Prostate Cancer: Circulating Tumor Cells as a Surrogate Endpoint for Survival

Brian I. Rini, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Results From the KEYNOTE-426 Trial on Pembrolizumab Plus Axitinib vs Sunitinib

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Selpercatinib in RET Fusion–Positive NSCLC

KEYNOTE-024 Survival Update

Final Overall Survival Results of IMpower131 Trial in Advanced Squamous NSCLC

Addition of Durvalumab to Chemotherapy Improves OS in Patients With Extensive-Stage SCLC

5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC